RealTime Dynamix™: Multiple Sclerosis Q2 2017

This Spherix Global Insights report highlights responses from 104 neurologists about the evolving treatment patterns for disease-modifying therapies in MS. Each quarterly survey tracks key performance metrics and introduces new, variable content. Emphasis in the Q2 survey includes early launch metrics for Ocrevus, including initial reaction to the first report of PML.

Click the button below to view highlights from this quarter 2 report:

RTD: Multiple Sclerosis Q2 Spotlight

2017-07-24T18:36:45+00:00